Thomas Borody

From Wikipedia, the free encyclopedia

Thomas Borody is an Australian gastoenterologist based in Sydney who is noted for his work in novel therapies for gastrointestinal disorders.

1 Life
2 Triple therapy for H. pylori infection
3 Subsequent career
4 Current work
5 External links

[edit] Life

Borody was born in Poland and came to Australia with his family in 1960. He gained degrees in Science and Medicine from the University of New South Wales in the mid-1970s and then worked for nine years at St Vincent's Hospital in Sydney before understaking postgraduate research at Sydney's Garvan Institute of Medical Research and at the Mayo Clinic. He gained his Doctorate in Medicine in 1984.

[edit] Triple therapy for H. pylori infection

As a gastroenterologist, Borody is most famous for his development of the triple therapy for infection with Helicobacter pylori bacteria. The triple therapy, which was invented around 1987, is a combination of bismuth, metronidazole and tetracycline..

[edit] Subsequent career

In the 1990s and early 2000s Borody discovered a number of other drug combinations which have been demonstrated to be important in treating gastrointestinal disorders such as Crohn's disease. Dr. Borody has also pioneered an innovative treatment for Pseudomembranous colitis and Ulcerative colitis called Fecal bacteriotherapy which involves repopulating the gut with beneficial bacteria using fecal material from healthy individuals.

[edit] Current work

Borody currently operates a Sydney-based clinic focused on gastrointestinal disorders called the Centre for Digestive Diseases. In 2004 he became a founder of the Australian biotechnology company Giaconda, of which he remains the largest shareholder.